Aflac Reports Q4 2025 Earnings with Mixed Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Source: seekingalpha
Aflac Inc (AFL) shares rose by 3.00% and reached a 52-week high amid a challenging market environment, as both the Nasdaq-100 and S&P 500 indices experienced declines of 1.15% and 1.00%, respectively.
The company's Q4 2025 earnings report revealed a revenue decline of 9.9% year-over-year, totaling $4.9 billion, and a net earnings drop of 27.5% to $1.4 billion. Despite these challenges, Aflac Japan reported a significant 15.7% increase in new annualized premium sales, driven by the cancer insurance product Miraito, indicating potential for future growth. Additionally, Aflac announced a 5.2% increase in its dividend and a substantial share repurchase program, reflecting a commitment to shareholder value.
These mixed results suggest that while Aflac faces competitive pressures, its strategic focus on product innovation and capital management may bolster investor confidence in the long term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AFL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AFL
Wall Street analysts forecast AFL stock price to fall
11 Analyst Rating
3 Buy
5 Hold
3 Sell
Hold
Current: 115.610
Low
100.00
Averages
110.90
High
125.00
Current: 115.610
Low
100.00
Averages
110.90
High
125.00
About AFL
Aflac Incorporated provides financial protection to policyholders and customers through its subsidiaries in the United States and Japan. The Company's principal business is supplemental health and life insurance products. Its segments include Aflac Japan, which includes Aflac Life Insurance Japan Ltd. (ALIJ), and Aflac U.S., which includes American Family Life Assurance Company of Columbus (Aflac), American Family Life Assurance Company of New York (Aflac New York), Continental American Insurance Company (CAIC), Tier One Insurance Company (TOIC), and Aflac Benefits Solutions, Inc. (ABS). The Aflac Japan segment is the insurer in Japan in terms of cancer and medical (third sector insurance products) policies in force. The Company designs its United States insurance products to provide supplemental coverage for people who already have major medical or primary insurance coverage, as Aflac U.S. insurance policies pay benefits regardless of other insurance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aflac Executives to Participate in Morgan Stanley Conference
- Executive Participation: Aflac President Virgil R. Miller and CFO Max Brodén will participate in the Morgan Stanley U.S. Financials Conference on June 9, 2026, showcasing the company's leadership in financial services and likely attracting investor interest.
- Live Webcast Arrangement: The event will be webcast live, allowing investors to register and view the presentation, which enhances transparency and interaction with stakeholders, thereby improving the company's public image.
- Industry Leadership: Aflac is the number one provider of supplemental health insurance products in the U.S. and leads in cancer and medical insurance in Japan, demonstrating its strong competitive position in global markets.
- Ethical Company Recognition: Aflac has been recognized as one of the World's Most Ethical Companies for 20 consecutive years and named one of Fortune's Most Admired Companies in 2026, highlighting its commitment to corporate social responsibility and sustainability.
See More
Aflac Executives to Participate in Morgan Stanley Financial Conference
- Executive Participation: Aflac President Virgil R. Miller and CFO Max Brodén will participate in the Morgan Stanley U.S. Financials Conference on June 9, 2026, showcasing the company's leadership in the financial services sector and likely attracting investor interest.
- Live Webcast Arrangement: The event will be webcast live, allowing investors to register 15 minutes prior to the presentation, which enhances company transparency and investor engagement.
- Company Background: Aflac, a Fortune 500 company, has provided financial protection to millions of policyholders, particularly in the U.S. and Japan, reinforcing its significant market position.
- Ethical Business Recognition: Aflac has been recognized as one of the World's Most Ethical Companies for 20 consecutive years, demonstrating its commitment to corporate social responsibility and sustainability, thereby enhancing brand image and customer trust.
See More
Aflac Issues ¥65.9B Yen Bonds Amid Strong Demand
- Bond Issuance Scale: Aflac successfully issued approximately ¥65.9 billion ($415 million) in yen-denominated bonds across four tranches on Thursday, indicating sustained investor demand for foreign credit.
- Interest Rate Level: The transaction featured a 10-year coupon of roughly 3.482%, reflecting the attractiveness of Japan's bond market, particularly amid changing global interest rate environments.
- Market Participation: Aflac's bond issuance follows Alphabet's $3.6 billion yen bond deal, highlighting a growing trend of foreign issuers tapping into Japan's bond market.
- Strategic Goals: Aflac aims to target sales in Japan closer to ¥80 billion while expanding its reinsurance franchise, intending to further solidify its position in the Japanese market.
See More
Aflac Faces Performance Decline Risks
- Declining Net Premiums: Aflac's net premiums earned have decreased by 6.2% annually over the past five years, significantly underperforming the broader insurance industry, indicating weaknesses in policy underwriting that could further harm future profitability.
- Unfavorable Revenue Projections: Wall Street analysts forecast a 2.7% drop in Aflac's revenue over the next 12 months, contrasting with the flat results of the past two years, suggesting that the company's products and services may face demand headwinds that could impact overall financial health.
- Book Value Per Share Decline: Consensus estimates predict Aflac's book value per share will shrink by 4.8% to $54.37 in the next 12 months, reflecting challenges in profit margin maintenance and investment portfolio management, which may undermine investor confidence.
- Lagging Market Performance: Although Aflac's stock trades at $115.26 with a forward P/B ratio of 2, its recent performance has lagged behind the S&P 500's 9.9% gain, prompting analysts to suggest that investors consider other more promising investment opportunities.
See More
Aflac Misses Q1 Revenue Expectations, Faces Challenges
- Revenue Shortfall: Aflac's Q1 revenue of $4.24 billion fell 1.8% year-over-year and missed analyst expectations of $4.32 billion, indicating challenges in maintaining revenue growth that could impact investor confidence moving forward.
- Profitability Decline: The adjusted EPS of $1.75 was 2.5% below the expected $1.80, reflecting pressures on cost control and sales growth, which may lead to short-term stock price pressure as investors reassess the company's performance.
- Sales Growth in Japan: Strong sales momentum in Japan, particularly from new medical and cancer insurance products, saw a 25.5% increase; however, persistency and lapse issues prevented a corresponding rise in earned premiums, highlighting a gap between market potential and actual performance.
- Reinsurance Strategy Expansion: Aflac executed its first third-party reinsurance deal in Japan, which, while having a minor short-term financial impact, is viewed by management as a strategic platform for future growth and diversification of earnings, indicating a forward-looking approach in their strategic planning.
See More
Aflac Reports Mixed Q1 Earnings Amid Yen Weakness
- Earnings Performance: Aflac's adjusted earnings per diluted share rose 5.4% year-over-year to $1.75, although this fell short of the Visible Alpha consensus of $1.80, indicating pressure on the company's profitability.
- Exchange Rate Impact: The average yen/dollar exchange rate was 156.87, 2.8% weaker than last year's 152.40, negatively impacting adjusted EPS by $0.02, reflecting the direct effect of currency fluctuations on financial results.
- Revenue Growth: The company reported revenue of $4.35 billion for the first quarter, a 27.9% increase year-over-year, surpassing market expectations of $4.32 billion, indicating strong performance in revenue generation.
- Premium Variations: Net earned premiums in Japan decreased by 6.4% to $1.6 billion, while net earned premiums in the U.S. increased by 3.5% to $1.6 billion, highlighting performance disparities across different markets and their impact on overall results.
See More
Aflac Executives to Participate in Morgan Stanley Conference
- Executive Participation: Aflac President Virgil R. Miller and CFO Max Brodén will participate in the Morgan Stanley U.S. Financials Conference on June 9, 2026, showcasing the company's leadership in financial services and likely attracting investor interest.
- Live Webcast Arrangement: The event will be webcast live, allowing investors to register and view the presentation, which enhances transparency and interaction with stakeholders, thereby improving the company's public image.
- Industry Leadership: Aflac is the number one provider of supplemental health insurance products in the U.S. and leads in cancer and medical insurance in Japan, demonstrating its strong competitive position in global markets.
- Ethical Company Recognition: Aflac has been recognized as one of the World's Most Ethical Companies for 20 consecutive years and named one of Fortune's Most Admired Companies in 2026, highlighting its commitment to corporate social responsibility and sustainability.
See More
Aflac Executives to Participate in Morgan Stanley Financial Conference
- Executive Participation: Aflac President Virgil R. Miller and CFO Max Brodén will participate in the Morgan Stanley U.S. Financials Conference on June 9, 2026, showcasing the company's leadership in the financial services sector and likely attracting investor interest.
- Live Webcast Arrangement: The event will be webcast live, allowing investors to register 15 minutes prior to the presentation, which enhances company transparency and investor engagement.
- Company Background: Aflac, a Fortune 500 company, has provided financial protection to millions of policyholders, particularly in the U.S. and Japan, reinforcing its significant market position.
- Ethical Business Recognition: Aflac has been recognized as one of the World's Most Ethical Companies for 20 consecutive years, demonstrating its commitment to corporate social responsibility and sustainability, thereby enhancing brand image and customer trust.
See More
Aflac Issues ¥65.9B Yen Bonds Amid Strong Demand
- Bond Issuance Scale: Aflac successfully issued approximately ¥65.9 billion ($415 million) in yen-denominated bonds across four tranches on Thursday, indicating sustained investor demand for foreign credit.
- Interest Rate Level: The transaction featured a 10-year coupon of roughly 3.482%, reflecting the attractiveness of Japan's bond market, particularly amid changing global interest rate environments.
- Market Participation: Aflac's bond issuance follows Alphabet's $3.6 billion yen bond deal, highlighting a growing trend of foreign issuers tapping into Japan's bond market.
- Strategic Goals: Aflac aims to target sales in Japan closer to ¥80 billion while expanding its reinsurance franchise, intending to further solidify its position in the Japanese market.
See More
Aflac Faces Performance Decline Risks
- Declining Net Premiums: Aflac's net premiums earned have decreased by 6.2% annually over the past five years, significantly underperforming the broader insurance industry, indicating weaknesses in policy underwriting that could further harm future profitability.
- Unfavorable Revenue Projections: Wall Street analysts forecast a 2.7% drop in Aflac's revenue over the next 12 months, contrasting with the flat results of the past two years, suggesting that the company's products and services may face demand headwinds that could impact overall financial health.
- Book Value Per Share Decline: Consensus estimates predict Aflac's book value per share will shrink by 4.8% to $54.37 in the next 12 months, reflecting challenges in profit margin maintenance and investment portfolio management, which may undermine investor confidence.
- Lagging Market Performance: Although Aflac's stock trades at $115.26 with a forward P/B ratio of 2, its recent performance has lagged behind the S&P 500's 9.9% gain, prompting analysts to suggest that investors consider other more promising investment opportunities.
See More
Aflac Misses Q1 Revenue Expectations, Faces Challenges
- Revenue Shortfall: Aflac's Q1 revenue of $4.24 billion fell 1.8% year-over-year and missed analyst expectations of $4.32 billion, indicating challenges in maintaining revenue growth that could impact investor confidence moving forward.
- Profitability Decline: The adjusted EPS of $1.75 was 2.5% below the expected $1.80, reflecting pressures on cost control and sales growth, which may lead to short-term stock price pressure as investors reassess the company's performance.
- Sales Growth in Japan: Strong sales momentum in Japan, particularly from new medical and cancer insurance products, saw a 25.5% increase; however, persistency and lapse issues prevented a corresponding rise in earned premiums, highlighting a gap between market potential and actual performance.
- Reinsurance Strategy Expansion: Aflac executed its first third-party reinsurance deal in Japan, which, while having a minor short-term financial impact, is viewed by management as a strategic platform for future growth and diversification of earnings, indicating a forward-looking approach in their strategic planning.
See More
Aflac Reports Mixed Q1 Earnings Amid Yen Weakness
- Earnings Performance: Aflac's adjusted earnings per diluted share rose 5.4% year-over-year to $1.75, although this fell short of the Visible Alpha consensus of $1.80, indicating pressure on the company's profitability.
- Exchange Rate Impact: The average yen/dollar exchange rate was 156.87, 2.8% weaker than last year's 152.40, negatively impacting adjusted EPS by $0.02, reflecting the direct effect of currency fluctuations on financial results.
- Revenue Growth: The company reported revenue of $4.35 billion for the first quarter, a 27.9% increase year-over-year, surpassing market expectations of $4.32 billion, indicating strong performance in revenue generation.
- Premium Variations: Net earned premiums in Japan decreased by 6.4% to $1.6 billion, while net earned premiums in the U.S. increased by 3.5% to $1.6 billion, highlighting performance disparities across different markets and their impact on overall results.
See More
